Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Психоневрологический диспансер Красногвардейского района Санкт-Петербурга; Кафедра психиатрии и наркологии медицинского факультета Санкт-Петербургского государственного университета
Список исп. литературыСкрыть список 1. Стандарты оказания помощи больным шизофренией. Московский НИИ психиатрии Росздрава. Под ред. В.Н.Краснова, И.Я. Гуровича, С.Н.Мосолова, А.Б.Шмуклера. М.: 2006. 2. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 (4): 1–63. 3. Andreason NC, Carpenter Jr, Kane JM et al. Remission in schizophrenia: proposed rationale and criteria for consensus. Am J Psychiatry 2005; 162: 441–9. 4. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553–64. 5. Davis JM, Matalon L, Watanabe MD et al. Depot antipsychotic drugs: place in therapy. Drugs 1994; 47 (5): 741–73. 6. Duncan JC, Rogers R. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. J Forensic Sci 1998; 46 (3): 1133–7. 7. Ereshefsky L, Saklad SR, Jann MW et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984; 45 (5): 50–9. 8. Fleishhacker WW, Eerdeckens M, Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64 (10): 1250–7. 9. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6. 10. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53 (12): 426–33. 11. Hogarty GE, Anderson CM, Reiss DJ et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia: II. Two-year effects of a controlled study on relapse and adjustment. Environmental-Personal Indicators in the Course of Schizophrenia (EPICS) Research Group. Arch Gen Psychiatry 1991; 48 (4): 340–7. 12. Johnson DA, Pasterski G, Ludlow JM et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983; 67 (5): 339–52. 13. Kelly GR, Scott JE, Mamon J. Medication compliance and health education among outpatients with chronic mental disorders. Med Care 1990; 28 (12): 1181–97. 14. Kissling W. Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 1997; 89 (Suppl. 382): 16–24. 15. Leucht S, Barnes TRE, Kissling W et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209–22. 16. Olivares JM, Rodriguez A, Povey M et al. 6-month follow-up from the electronic- Schizophrenia Adherence Treatment Registry (e-STAR) of patients in Spain who were initiated to Risperidone Long-Acting Injection (RLAI). 9th ISPOR European Congress, Copenhagen, Denmark 2006. e-STAR Spain cohort, Draft 1. 17. Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Бремя шизофрении и психотических расстройств в странах Евросоюза (расширенный реферат). Психиатр. и психофармакотер. 2006; 11 (2). 18. Weiden PJ, Dixon L, Frances A et al. Neuroleptic noncompliance in schizophrenia. In: Tamming CA, Schulz SC, editors. Advances in neuropsychiatry and psychopharmacology: schizophrenia research. New York: Raven Press 1991: 1: 285–96. 19. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21 (3): 419–29. 20. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986; 14 (2): 105–22. 21. Yousef HA. A five-year follow-up study of chronic schizophrenics and other psychotics treated in the community: depot haloperidol decanoate versus other neuroleptics. Adv Ther 1989; 67: 186–95.